MA33619B1 - Agent thérapeutique pour des troubles de l'anxiété - Google Patents

Agent thérapeutique pour des troubles de l'anxiété

Info

Publication number
MA33619B1
MA33619B1 MA34734A MA34734A MA33619B1 MA 33619 B1 MA33619 B1 MA 33619B1 MA 34734 A MA34734 A MA 34734A MA 34734 A MA34734 A MA 34734A MA 33619 B1 MA33619 B1 MA 33619B1
Authority
MA
Morocco
Prior art keywords
anxiety disorders
therapeutic agent
therapeutic
pharmaceutically acceptable
disclosed
Prior art date
Application number
MA34734A
Other languages
Arabic (ar)
English (en)
Inventor
Junya Kase
Tomoyuki Kanda
Original Assignee
Kyowa Hakko Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43649340&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33619(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kyowa Hakko Kirin Co Ltd filed Critical Kyowa Hakko Kirin Co Ltd
Publication of MA33619B1 publication Critical patent/MA33619B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

L'invention porte sur un agent therapeutique et/ou prophylatique pour des troubles de l'anxiete, qui contient un derive de thiazole represente par la formule generale (i) (dans laquelle r1 représente un groupe aryle ou similaire) ou un sel pharmaceutiquement acceptable de celui-ci comme ingrédient actif.
MA34734A 2009-09-02 2012-03-30 Agent thérapeutique pour des troubles de l'anxiété MA33619B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009202894 2009-09-02
PCT/JP2010/064989 WO2011027806A1 (fr) 2009-09-02 2010-09-02 Agent thérapeutique pour des troubles de l'anxiété

Publications (1)

Publication Number Publication Date
MA33619B1 true MA33619B1 (fr) 2012-09-01

Family

ID=43649340

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34734A MA33619B1 (fr) 2009-09-02 2012-03-30 Agent thérapeutique pour des troubles de l'anxiété

Country Status (31)

Country Link
US (1) US20120172362A1 (fr)
EP (1) EP2474544B1 (fr)
JP (1) JP5663485B2 (fr)
KR (2) KR20170044768A (fr)
CN (1) CN102482271A (fr)
AU (1) AU2010290424C1 (fr)
BR (1) BR112012004850A2 (fr)
CA (1) CA2772922C (fr)
CL (1) CL2012000533A1 (fr)
CY (1) CY1119483T1 (fr)
DK (1) DK2474544T3 (fr)
DO (1) DOP2012000056A (fr)
EA (1) EA023728B1 (fr)
ES (1) ES2643840T3 (fr)
GE (1) GEP20156225B (fr)
HR (1) HRP20171418T1 (fr)
HU (1) HUE036543T2 (fr)
IL (1) IL218320A (fr)
LT (1) LT2474544T (fr)
MA (1) MA33619B1 (fr)
ME (1) ME02877B (fr)
MX (1) MX2012002529A (fr)
NZ (1) NZ598754A (fr)
PL (1) PL2474544T3 (fr)
PT (1) PT2474544T (fr)
RS (1) RS56401B1 (fr)
SI (1) SI2474544T1 (fr)
TN (1) TN2012000093A1 (fr)
UA (1) UA113383C2 (fr)
WO (1) WO2011027806A1 (fr)
ZA (1) ZA201202347B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE025659T2 (en) * 2003-12-26 2016-04-28 Kyowa Hakko Kirin Co Ltd Thiazole derivatives
MA41090A (fr) * 2014-12-03 2017-10-10 H Lundbeck As Antagoniste de a2a faiblement dosé pour le traitement du tdah et de la maladie de parkinson
JOP20200093A1 (ar) 2015-01-09 2017-06-16 Kyowa Kirin Co Ltd طريقة لإنتاج مشتق ثيازول
JO3544B1 (ar) * 2015-03-19 2020-07-05 Kyowa Kirin Co Ltd عامل علاجي للاختلال الوظيفي في الفص الجبهي
BR112021004999A2 (pt) 2018-09-17 2021-06-08 Yungjin Pharm. Co., Ltd. composto e método de inibição de cdk7 em um sujeito

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2116967C (fr) 1992-07-08 2003-08-19 Fumio Suzuki Antidepresseurs
DE69834500T2 (de) 1997-09-05 2007-05-03 Kyowa Hakko Kogyo Co., Ltd. Xanthinderivative zur behandlung von hirnischämie
US20040152659A1 (en) * 1999-05-12 2004-08-05 Fujisawa Pharmaceutical Co. Ltd. Method for the treatment of parkinson's disease comprising administering an A1A2a receptor dual antagonist
AU4431000A (en) * 1999-05-12 2000-12-05 Fujisawa Pharmaceutical Co., Ltd. Novel use
JP2005516891A (ja) 2001-09-13 2005-06-09 シェーリング　コーポレイション アデノシンＡ２ａレセプタアンタゴニストと抗鬱薬または抗不安薬との組合せ
US6620811B2 (en) 2001-11-19 2003-09-16 Hoffmann-La Roche Inc. Isonicotin- and nicotinamide derivatives of benzothiazoles
MXPA05013148A (es) * 2003-06-10 2006-03-17 Kyowa Hakko Kogyo Kk Un metodo de tratamiento de un trastorno de la ansiedad.
HUE025659T2 (en) * 2003-12-26 2016-04-28 Kyowa Hakko Kirin Co Ltd Thiazole derivatives
JPWO2006137527A1 (ja) * 2005-06-23 2009-01-22 協和発酵キリン株式会社 チアゾール誘導体
LT1921077T (lt) * 2005-08-02 2017-09-25 Kyowa Hakko Kirin Co., Ltd. Agentas, skirtas miego sutrikimo gydymui ir (arba) prevencijai
UA110097C2 (uk) * 2009-09-02 2015-11-25 Терапевтичний агент для лікування розладів настрою

Also Published As

Publication number Publication date
ZA201202347B (en) 2015-11-25
CA2772922A1 (fr) 2011-10-03
KR20170044768A (ko) 2017-04-25
EA023728B1 (ru) 2016-07-29
AU2010290424C1 (en) 2016-02-18
WO2011027806A1 (fr) 2011-03-10
EP2474544B1 (fr) 2017-07-12
KR20120047311A (ko) 2012-05-11
EP2474544A4 (fr) 2013-01-23
UA113383C2 (xx) 2017-01-25
BR112012004850A2 (pt) 2020-06-23
MX2012002529A (es) 2012-04-11
DK2474544T3 (en) 2017-10-02
CL2012000533A1 (es) 2012-09-14
IL218320A0 (en) 2012-04-30
ES2643840T3 (es) 2017-11-24
CN102482271A (zh) 2012-05-30
PT2474544T (pt) 2017-10-03
HUE036543T2 (hu) 2018-07-30
GEP20156225B (en) 2015-01-26
JP5663485B2 (ja) 2015-02-04
ME02877B (fr) 2018-04-20
AU2010290424B2 (en) 2015-11-05
CA2772922C (fr) 2017-11-21
EA201270360A1 (ru) 2012-09-28
EP2474544A1 (fr) 2012-07-11
DOP2012000056A (es) 2012-06-30
RS56401B1 (sr) 2018-01-31
LT2474544T (lt) 2017-10-25
NZ598754A (en) 2014-08-29
CY1119483T1 (el) 2018-03-07
US20120172362A1 (en) 2012-07-05
HRP20171418T1 (hr) 2017-11-03
PL2474544T3 (pl) 2017-12-29
JPWO2011027806A1 (ja) 2013-02-04
AU2010290424A1 (en) 2012-04-19
SI2474544T1 (sl) 2017-11-30
IL218320A (en) 2016-06-30
TN2012000093A1 (en) 2013-09-19

Similar Documents

Publication Publication Date Title
TN2013000393A1 (fr) Derives de la pyrazolospirocetone pour une utilisation comme inhibiteurs de l'acetyl-coa carboxylase
MA33734B1 (fr) N1-pyrazolospirocétone inhibitrices d'acétyl-coa carboxylase
MX2010004232A (es) Compuesto de indolina de pirimidilo.
MA33618B1 (fr) Agent thérapeutique destiné aux troubles de l'humeur
MY148480A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
CY1110014T1 (el) Παραγωγα τετραϋδροκαρβαζολιου χρησιμα ως τροποποιητες υποδοχεα ανδρογονων (sarm)
DE602006003432D1 (de) Latoren des androgenrezeptors
DK1780197T3 (da) 5-Substituerede 2-phenylamino-benzamider som MEK-inhibitorer
BRPI0513433A (pt) derivados de hidantoìna para o tratamento de distúrbios inflamatórios
MA30717B1 (fr) Derives de pyridin-3-yle en tant qu'agents immunomodulateurs
MA33619B1 (fr) Agent thérapeutique pour des troubles de l'anxiété
MA30718B1 (fr) Derives de pyridin-4-yle en tant qu'agents immunomodulateurs.
SG151336A1 (en) 1,3,4-oxadiazol-2-ones as ppar delta
EA200900152A1 (ru) Ингибиторы пирролотриазинкиназы
HRP20090281T1 (en) 1,2,3,4-tetrasubstituted indole for the treatment of respiratory diseases
MA32240B1 (fr) Inhibiteurs de désacétylases b à base d'hydroxamate
MA30821B1 (fr) Derives de pyrazoline utiles comme antagonistes des recepteurs de mineralocorticoïdes
NO20064982L (no) 1,3,4-oksadiazol-2-oner som PPAR delta modulatorer og anvendelse derav
EP2639229A3 (fr) Dérivé de thiazole et son utilisation en tant qu'inhibiteur VAP-1
MX2007005073A (es) Conjugados con actividad antiinflamtoria.
WO2008079873A3 (fr) Utilisation de composés thiazolyle comme inhibiteurs de kinases
MA30540B1 (fr) Derives de quinolines et compositions pharmaceutiques de ces derives.
EA200800071A1 (ru) Производные бензофуранила как ингибиторы 5-нт6-рецептора
MA30797B1 (fr) Nouveaux derives indoliques , leur procede de preparation et les compositions pharmaceutiques qui les contiennent
TW200635592A (en) Pyridyl-substituted spiro-hydantoin compounds and use thereof